B. Metzler seel. Sohn & Co. Holding AG Purchases New Stake in ResMed Inc. (NYSE:RMD)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,025 shares of the medical equipment provider's stock, valued at approximately $1,715,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. UMB Bank n.a. grew its stake in shares of ResMed by 1.9% in the third quarter. UMB Bank n.a. now owns 2,465 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 47 shares during the last quarter. QRG Capital Management Inc. grew its stake in shares of ResMed by 4.5% in the second quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider's stock worth $247,000 after acquiring an additional 56 shares during the last quarter. Inspire Advisors LLC grew its stake in shares of ResMed by 1.9% in the second quarter. Inspire Advisors LLC now owns 3,060 shares of the medical equipment provider's stock worth $586,000 after acquiring an additional 56 shares during the last quarter. Concurrent Investment Advisors LLC grew its stake in shares of ResMed by 3.1% in the third quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider's stock worth $469,000 after acquiring an additional 57 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its stake in shares of ResMed by 2.0% in the third quarter. Moss Adams Wealth Advisors LLC now owns 3,043 shares of the medical equipment provider's stock worth $743,000 after acquiring an additional 60 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Baird R W upgraded shares of ResMed to a "strong-buy" rating in a research note on Tuesday, September 24th. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a research report on Friday, October 25th. Robert W. Baird raised their target price on ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a research report on Friday, October 25th. StockNews.com raised ResMed from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. Finally, Bank of America raised their target price on ResMed from $240.00 to $270.00 and gave the stock a "buy" rating in a research report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $225.70.

Insider Activity at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $239.90, for a total value of $479,800.00. Following the transaction, the director now owns 87,204 shares in the company, valued at $20,920,239.60. This trade represents a 2.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Witte Jan De sold 796 shares of the firm's stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the transaction, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. This represents a 10.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,174 shares of company stock valued at $14,882,278 over the last ninety days. 0.71% of the stock is owned by insiders.

ResMed Price Performance

Shares of NYSE RMD traded up $0.18 during midday trading on Friday, reaching $243.78. 551,442 shares of the company traded hands, compared to its average volume of 1,116,007. The firm has a market cap of $35.79 billion, a PE ratio of 32.29, a PEG ratio of 1.77 and a beta of 0.69. The stock's 50-day simple moving average is $241.86 and its 200-day simple moving average is $224.42. ResMed Inc. has a 12 month low of $151.95 and a 12 month high of $260.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.19 billion. During the same period last year, the business earned $1.64 earnings per share. The business's revenue was up 11.1% on a year-over-year basis. As a group, equities analysts anticipate that ResMed Inc. will post 9.28 earnings per share for the current fiscal year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.87%. ResMed's dividend payout ratio is 28.08%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.